Explore Mutual Funds

Bajaj Finserv Healthcare Fund-Reg(G)

As on Jun-24-2025 change fund
9.44  up0.01 (0.07%)
BUY

fund objective

The objective of the Scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.

riskometer

Investors understand that their principal will be at very high risk

5-Years History
financial year2024-2025
NAV in Rs (as on 31-Mar)9.08
Net Assets(Rs Crores) (as on 31-Mar) 307.40
Scheme Returns(%)(Absolute)-9.21
B'mark Returns(%)(Absolute)NA
Category Rank95/102
Quarterly performance - Last 5 years (Absolute Ret. in %)
financial year Q1 Q2 Q3 Q4
2024-2025NANANA-10.08
Top 10 holdings
company (%)
Divi's Laboratories Ltd.8.71 
Sun Pharmaceutical Industries...7.82 
Cipla Ltd.6.61 
Apollo Hospitals Enterprise Ltd.5.86 
Dr. Reddy's Laboratories Ltd.3.52 
Piramal Pharma Ltd.3.50 
Biocon Ltd.3.43 
Emcure Pharmaceuticals Ltd.3.40 
Glenmark Pharmaceuticals Ltd.2.81 
Neuland Laboratories Ltd.2.76 

Category

Sector Funds

Launch Date

27-Dec-24

Scheme Benchmark

NA

AUM ( in Cr.)

321.02

portfolio price to book value

9.46

investing style?

Large Growth

fund manager?

Nimesh Chandan,Sorbh Gupta,Siddharth Chaudhary

expense ratio %

2.37

Top 10 sectors
sectors (%)
Pharmaceuticals & Drugs67.62
Hospital & Healthcare Services14.55
Business Support3.99
Consumer Food3.87
Household & Personal Products2.96
Plastic Products1.56
Chemicals0.49
Fintech0.44

Growth Chart of the Scheme vis a vis benchmark (SIP value 10,000)

to go
  • 1M
  • 3M
  • 6M
  • 1Y
  • 3Y
  • 5Y
  • 10Y
  • maximum
performance comparison with similar schemes
scheme name investment style inception date AUM in Cr. 1Y(%) 3Y(%) 5Y(%) 10Y(%) since inception
Bajaj Finserv Healthcare Fund-Reg(G)Large-Growth 27-Dec-2024321.02NANANANA-5.61BUY
ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund-(G)Large-Growth 13-Jul-20185,507.5220.9229.1424.19NA21.50BUY
SBI Healthcare Opp Fund-Reg(G)Large-Growth 14-Jul-19993,689.2817.8527.8423.3011.6316.19BUY
Nippon India Pharma Fund(G)Large-Growth 05-Jun-20048,352.1614.1024.6821.4814.3520.48BUY
Tata India Pharma & Healthcare Fund-Reg(G)Large-Growth 28-Dec-20151,231.6712.9524.0721.06NA12.05BUY
ITI Pharma & Healthcare Fund-Reg(G)Large-Growth 08-Nov-2021220.8514.9722.80NANA13.85BUY
Aditya Birla SL Pharma & Healthcare Fund-Reg(G)Large-Growth 10-Jul-2019814.1810.1422.3418.73NA20.14BUY
HDFC Pharma and Healthcare Fund-Reg(G)Large-Growth 04-Oct-20231,704.8725.71NANANA33.23BUY
WOC Pharma and Healthcare Fund-Reg(G)Large-Growth 06-Feb-2024331.6624.52NANANA21.62BUY
Kotak Healthcare Fund-Reg(G)Large-Growth 11-Dec-2023434.5513.57NANANA19.24BUY
Quant Healthcare Fund-Reg(G)Large-Growth 17-Jul-2023417.033.31NANANA24.68BUY
PGIM India Healthcare Fund-Reg(G)Large-Growth 06-Dec-2024108.88NANANANA-3.40BUY
disclaimer

Finmoksha financial services, is an AMFI registered distributor with ARN No. 143367 through its proprietor Gopal Kumar Agrawal

The firm does not furnish any guaranties, warranties or representations, express or implied, on products offered through the Finmoksha platform. The firm accepts no liability for any damages or losses however caused, in connection with investments made through the platform. Terms and conditions of the platform are applicable at all times.

Mutual fund and other investments are always subject to market risks. Please read all, Scheme Information Documents (SID), Key Information Memorandum (KIM), Addendums (if any) issued thereto from time to time and any other related documents or information carefully before investing. Past performance is not indicative or assurance of future performance or returns. Please consider your specific investment requirements, risk appetite and time horizon before choosing a scheme of mutual fund or any other investment.

ARN No. 143367    

Copyrights © 2018 Finmoksha Financial Services. All Right Reserved
Designed, Developed & Content Powered By  Accord Fintech Pvt. Ltd.